Suppression of P53 Pathway is an Important Factor Inducing Acute Graft-versus-Host Disease Through T Cell Activation Based on Bioinformatics Analysis

References

• Malard F, Holler E, Sandmaier BM, Huang H, Mohty M. Acute graft-versus-host disease. Nat Rev Dis Primers. 2023;9(1):27. doi:10.1038/s41572-023-00438-1
   PubMedGoogle Scholar
• Srinagesh HK, Levine JE, Ferrara JLM. Biomarkers in acute graft-versus-host disease: new insights. Ther Adv Hematol. 2019;10:2040620719891358. doi:10.1177/2040620719891358
   Web of Science ®Google Scholar
• Toubai T, Tawara I, Sun Y, et al. Induction of acute GVHD by sex-mismatched H-Y antigens in the absence of functional radiosensitive host hematopoietic-derived antigen-presenting cells. Blood. 2012;119(16):3844–3853. doi:10.1182/blood-2011-10-384057
   PubMed Web of Science ®Google Scholar
• Coghill JM, Sarantopoulos S, Moran TP, Murphy WJ, Blazar BR, Serody JS. Effector CD4+ T cells, the cytokines they generate, and GVHD: something old and something new. Blood. 2011;117(12):3268–3276. doi:10.1182/blood-2010-12-290403
   PubMed Web of Science ®Google Scholar
• Bashey A, Zhang X, Sizemore CA, et al. T-cell-replete HLA-haploidentical hematopoietic transplantation for hematologic malignancies using post-transplantation cyclophosphamide results in outcomes equivalent to those of contemporaneous HLA-matched related and unrelated donor transplantation. J Clin Oncol. 2013;31(10):1310–1316. doi:10.1200/JCO.2012.44.3523
   PubMed Web of Science ®Google Scholar
• Soiffer RJ, Kim HT, McGuirk J, et al. Prospective, randomized, double-blind, phase iii clinical trial of anti-T-lymphocyte globulin to assess impact on chronic graft-versus-host disease-free survival in patients undergoing HLA-matched unrelated myeloablative hematopoietic cell transplantation. J Clin Oncol. 2017;35(36):4003–4011. doi:10.1200/JCO.2017.75.8177
   PubMed Web of Science ®Google Scholar
• Walker I, Panzarella T, Couban S, et al. Pretreatment with anti-thymocyte globulin versus no anti-thymocyte globulin in patients with haematological malignancies undergoing haemopoietic cell transplantation from unrelated donors: a randomised, controlled, open-label, Phase 3, multicentre trial. Lancet Oncol. 2016;17(2):164–173. doi:10.1016/S1470-2045(15)00462-3
   PubMed Web of Science ®Google Scholar
• Green DR, Kroemer G. Cytoplasmic functions of the tumour suppressor p53. Nature. 2009;458(7242):1127–1130. doi:10.1038/nature07986
   PubMed Web of Science ®Google Scholar
• Vousden KH, Prives C. Blinded by the Light: the Growing Complexity of p53. Cell. 2009;137(3):413–431. doi:10.1016/j.cell.2009.04.037
   PubMed Web of Science ®Google Scholar
• Kawashima H, Takatori H, Suzuki K, et al. Tumor suppressor p53 inhibits systemic autoimmune diseases by inducing regulatory T cells. J Immunol. 2013;191(7):3614–3623. doi:10.4049/jimmunol.1300509
   PubMed Web of Science ®Google Scholar
• Hoffmann P, Ermann J, Edinger M, Fathman CG, Strober S. Donor-type CD4(+)CD25(+) regulatory T cells suppress lethal acute graft-versus-host disease after allogeneic bone marrow transplantation. J Exp Med. 2002;196(3):389–399. doi:10.1084/jem.20020399
   PubMed Web of Science ®Google Scholar
• Liu Y, Cai Y, Dai L, et al. The expression of Th17-associated cytokines in human acute graft-versus-host disease. Biol Blood Marrow Transplant. 2013;19(10):1421–1429. doi:10.1016/j.bbmt.2013.06.013
   PubMed Web of Science ®Google Scholar
• Edinger M, Hoffmann P, Ermann J, et al. CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation. Nat Med. 2003;9(9):1144–1150. doi:10.1038/nm915
   PubMed Web of Science ®Google Scholar
• Pierini A, Strober W, Moffett C, et al. TNF-α priming enhances CD4+FoxP3+ regulatory T-cell suppressive function in murine GVHD prevention and treatment. Blood. 2016;128(6):866–871. doi:10.1182/blood-2016-04-711275
   PubMed Web of Science ®Google Scholar
• Jiang H, Fu D, Bidgoli A, Paczesny S. T cell subsets in graft versus host disease and graft versus tumor. Front Immunol. 2021;12:761448. doi:10.3389/fimmu.2021.761448
   PubMed Web of Science ®Google Scholar
• Carlson MJ, West ML, Coghill JM, Panoskaltsis-Mortari A, Blazar BR, Serody JS. In vitro-differentiated TH17 cells mediate lethal acute graft-versus-host disease with severe cutaneous and pulmonary pathologic manifestations. Blood. 2009;113(6):1365–1374. doi:10.1182/blood-2008-06-162420
   PubMed Web of Science ®Google Scholar
• Park JS, Lim MA, Cho ML, et al. p53 controls autoimmune arthritis via STAT-mediated regulation of the Th17 cell/Treg cell balance in mice. Arthritis Rheum. 2013;65(4):949–959. doi:10.1002/art.37841
   PubMedGoogle Scholar
• Zhang S, Zheng M, Kibe R, et al. Trp53 negatively regulates autoimmunity via the STAT3-Th17 axis. FASEB j. 2011;25(7):2387–2398. doi:10.1096/fj.10-175299
   PubMed Web of Science ®Google Scholar
• Hua J, Chen Y, Fu B, et al. Downregulation of p53 by Insufficient CTCF in CD4 T cells is an important factor inducing acute graft-versus-host disease. Front Immunol. 2020;11:568637. doi:10.3389/fimmu.2020.568637
   PubMed Web of Science ®Google Scholar
• Wang R, Dillon CP, Shi LZ, et al. The transcription factor Myc controls metabolic reprogramming upon T lymphocyte activation. Immunity. 2011;35(6):871–882. doi:10.1016/j.immuni.2011.09.021
   PubMed Web of Science ®Google Scholar
• Yang K, Chi H. mTOR and metabolic pathways in T cell quiescence and functional activation. Semin Immunol. 2012;24(6):421–428. doi:10.1016/j.smim.2012.12.004
   PubMed Web of Science ®Google Scholar
• Michaloglou C, Crafter C, Siersbaek R, et al. Combined Inhibition of mTOR and CDK4/6 is required for optimal blockade of E2F function and long-term growth inhibition in estrogen receptor-positive breast cancer. Mol Cancer Ther. 2018;17(5):908–920. doi:10.1158/1535-7163.MCT-17-0537
   PubMed Web of Science ®Google Scholar
• Harris AC, Young R, Devine S, et al. International, multicenter standardization of acute graft-versus-host disease clinical data collection: a report from the mount sinai acute GVHD international consortium. Biol Blood Marrow Transplant. 2016;22(1):4–10. doi:10.1016/j.bbmt.2015.09.001
   PubMed Web of Science ®Google Scholar
• Schoemans HM, Lee SJ, Ferrara JL, et al. EBMT-NIH-CIBMTR Task Force position statement on standardized terminology & guidance for graft-versus-host disease assessment. Bone Marrow Transplant. 2018;53(11):1401–1415. doi:10.1038/s41409-018-0204-7
   PubMed Web of Science ®Google Scholar
• Leek JT, Johnson WE, Parker HS, Jaffe AE, Storey JD. The sva package for removing batch effects and other unwanted variation in high-throughput experiments. Bioinformatics. 2012;28(6):882–883. doi:10.1093/bioinformatics/bts034
   PubMed Web of Science ®Google Scholar
• Ritchie ME, Phipson B, Wu D, et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015;43(7):e47. doi:10.1093/nar/gkv007
   PubMed Web of Science ®Google Scholar
• Subramanian A, Tamayo P, Mootha VK, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005;102(43):15545–15550. doi:10.1073/pnas.0506580102
   PubMed Web of Science ®Google Scholar
• Yu G, Wang LG, Han Y, He QY. clusterProfiler: an R package for comparing biological themes among gene clusters. Omics. 2012;16(5):284–287. doi:10.1089/omi.2011.0118
   PubMed Web of Science ®Google Scholar
• Newman AM, Liu CL, Green MR, et al. Robust enumeration of cell subsets from tissue expression profiles. Nat Methods. 2015;12(5):453–457. doi:10.1038/nmeth.3337
   PubMed Web of Science ®Google Scholar
• Hänzelmann S, Castelo R, Guinney J. GSVA: gene set variation analysis for microarray and RNA-seq data. BMC Bioinf. 2013;14:7. doi:10.1186/1471-2105-14-7
   PubMed Web of Science ®Google Scholar
• Vlašić I, Horvat A, Tadijan A, Slade N. p53 Family in Resistance to Targeted Therapy of Melanoma. Int J Mol Sci. 2022;24(1):65. doi:10.3390/ijms24010065
   PubMed Web of Science ®Google Scholar
• Zhan Q, Korngold R, Lezcano C, McKeon F, Murphy GF. Graft-versus-host disease-related cytokine-driven apoptosis depends on p73 in cytokeratin 15-positive target cells. Biol Blood Marrow Transplant. 2012;18(6):841–851. doi:10.1016/j.bbmt.2012.02.004
   PubMed Web of Science ®Google Scholar
• Yang A, Walker N, Bronson R, et al. p73-deficient mice have neurological, pheromonal and inflammatory defects but lack spontaneous tumours. Nature. 2000;404(6773):99–103. doi:10.1038/35003607
   PubMed Web of Science ®Google Scholar
• Powell JD, Lerner CG, Schwartz RH. Inhibition of cell cycle progression by rapamycin induces T cell clonal anergy even in the presence of costimulation. J Immunol. 1999;162(5):2775–2784. doi:10.4049/jimmunol.162.5.2775
   PubMed Web of Science ®Google Scholar
• Cao Y, Trillo-Tinoco J, Sierra RA, et al. ER stress-induced mediator C/EBP homologous protein thwarts effector T cell activity in tumors through T-bet repression. Nat Commun. 2019;10(1):1280. doi:10.1038/s41467-019-09263-1
   PubMedGoogle Scholar
• Zhao E, Maj T, Kryczek I, et al. Cancer mediates effector T cell dysfunction by targeting microRNAs and EZH2 via glycolysis restriction. Nat Immunol. 2016;17(1):95–103. doi:10.1038/ni.3313
   PubMed Web of Science ®Google Scholar
• Huang L, Guo Z, Wang F, Fu L. KRAS mutation: from undruggable to druggable in cancer. Signal Transduct Target Ther. 2021;6(1):386. doi:10.1038/s41392-021-00780-4
   PubMed Web of Science ®Google Scholar
• Tzachanis D, Freeman GJ, Hirano N, et al. Tob is a negative regulator of activation that is expressed in anergic and quiescent T cells. Nat Immunol. 2001;2(12):1174–1182. doi:10.1038/ni730
   PubMed Web of Science ®Google Scholar
• Lozano-Ojalvo D, López-Fandiño R, López-Expósito I, et al. PBMC-Derived T Cells. In: Verhoeckx K, Cotter P, López-Expósito I, editors. The Impact of Food Bioactives on Health: In Vitro and ex vivo Models. Springer Nature; 2015:169–180.
   Google Scholar